Vaccinex Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Vaccinex are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Vaccinex has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Vaccinex is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 6.4 M |
Vaccinex |
Vaccinex Relative Risk vs. Return Landscape
If you would invest (100.00) in Vaccinex on April 26, 2025 and sell it today you would earn a total of 100.00 from holding Vaccinex or generate -100.0% return on investment over 90 days. Vaccinex is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Vaccinex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaccinex Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaccinex's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Vaccinex, and traders can use it to determine the average amount a Vaccinex's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VCNX |
Based on monthly moving average Vaccinex is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaccinex by adding Vaccinex to a well-diversified portfolio.
Vaccinex Fundamentals Growth
Vaccinex Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Vaccinex, and Vaccinex fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaccinex Pink Sheet performance.
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 | ||||
| Current Valuation | 1.59 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Price To Book | 7.34 X | ||||
| Price To Sales | 4.34 X | ||||
| Revenue | 570 K | ||||
| EBITDA | (19.75 M) | ||||
| Cash And Equivalents | 11.4 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 247 K | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | (2.59) X | ||||
| Cash Flow From Operations | (17.23 M) | ||||
| Earnings Per Share | 7.42 X | ||||
| Total Asset | 3.63 M | ||||
| Retained Earnings | (339.93 M) | ||||
Things to note about Vaccinex performance evaluation
Checking the ongoing alerts about Vaccinex for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Vaccinex help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vaccinex is not yet fully synchronised with the market data | |
| Vaccinex has some characteristics of a very speculative penny stock | |
| Vaccinex has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 570 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (13.7 M). | |
| Vaccinex currently holds about 11.4 M in cash with (17.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. |
- Analyzing Vaccinex's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaccinex's stock is overvalued or undervalued compared to its peers.
- Examining Vaccinex's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaccinex's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaccinex's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaccinex's pink sheet. These opinions can provide insight into Vaccinex's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Vaccinex Pink Sheet
If you are still planning to invest in Vaccinex check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccinex's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |